Opinion|Videos|March 14, 2025
Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC
Panelists discuss how the MARIPOSA trial (ASCO 2024) showed improved overall survival (OS) with amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant non–small cell lung cancer (NSCLC), supporting its FDA approval (October 2024). This regimen may become standard of care for select patients, but osimertinib with or without chemo remains vital. The complete response letter (CRL) for subcutaneous amivantamab may delay uptake.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the latest OS data from MARIPOSA andthe recentFDA approval (October 2024) of combination amivantamab and lazertinib as an advancement in the first-line treatment space.
- MARIPOSA Felip E, et al. ASCO 2024. Abs 8504; J&J press release, January 7, 2025
- Should this combination become the new standard of care for first-line treatment for certain patients?
- What is the remaining role for osimertinib with or without chemotherapy?
- How might the recent CRL for subcutaneous amivantamab impact clinical practice over the next year?
Advertisement
Related to this article
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.
Faculty members gathered at an OncLive Scientific Interchange and Workshop to discuss individualizing care in EGFR-mutated NSCLC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
2
FDA Flashback: Breast Cancer Decisions and News From June 2026
3
Interpreting Efficacy Data and Assessing Risk-Benefit in a Curative-Intent Population
4
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
5